CoronaryAtlas logo
CoronaryAtlas
Threonine
Pathway / Myocardial injury (shared endpoint)

Threonine

metabolite

Altered plasma amino acid metabolism reflects acute myocardial ischemic stress and cardiomyocyte injury.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencelow
RationaleAmino acid perturbation in acute ischemia; nonspecific myocardial stress marker.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — non-Type-I
11
A — assay feasibility
42
E — evidence strength
86
T1DI (composite)
19
Specificity differential (R−C)+3.9
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 0
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 0
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 3/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 3 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)